LABORATORIO REIG JOFRE (RJF) AI Stock Analysis

• Market Cap: €250.68M
• Dividend Yield: 1.28%
• Average Volume (3M): 38.42K
• Price to Earnings (P/E): 23.1
• Beta (1Y): 0.34
• Revenue Growth: 5.10%
• EPS Growth: 20.61%
• Country: ES
• Employees: 1,331
• Sector: Healthcare
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 80,895,750
• 10 Day Avg. Volume: 28,635
• 30 Day Avg. Volume: 38,422
• PEG Ratio: -0.72
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: €3.50 ▲(12.18%Upside)

The overall stock score of 75 reflects the strong financial performance and positive technical indicators, which are the most significant factors. The valuation is slightly elevated, indicating potential overvaluation, but the dividend yield provides some balance. The absence of earnings call and corporate events data did not impact the score.

LABORATORIO REIG JOFRE Business Overview & Revenue Model

Company Description

Laboratorio Reig Jofre (RJF) is a Spanish pharmaceutical company that focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company operates in three primary sectors: pharmaceuticals, specialty products, and consumer healthcare. Its core products include antibiotics, injectables, dermatological treatments, and nutritional supplements, catering to both health professionals and end consumers worldwide.

How the Company Makes Money

Reig Jofre generates revenue through the development, production, and sale of pharmaceutical and healthcare products. The company's key revenue streams include the sale of prescription medications, over-the-counter products, and consumer health products. It invests in research and development to innovate and expand its product portfolio, which helps maintain its competitive edge in the markets it serves. Additionally, Reig Jofre often relies on strategic partnerships and collaborations with other pharmaceutical companies and healthcare providers to enhance its distribution networks and market reach, thereby contributing to its overall earnings.

LABORATORIO REIG JOFRE Financial Statement Overview

Summary

LABORATORIO REIG JOFRE displays robust financial performance with consistent revenue and profit growth. The balance sheet is strong with manageable leverage and solid equity. Cash flow generation is healthy, providing ample liquidity for operations and investments. The company demonstrates strong financial health and growth potential in the Pharmaceuticals industry.

Income Statement

The company has demonstrated a strong revenue growth trajectory, with a notable increase from €316.09M to €338.90M year-over-year, marking a 7.22% growth rate. Gross Profit Margin is healthy at 57.73%, indicating efficient cost management. The Net Profit Margin improved to 3.06%, reflecting better profitability. EBIT and EBITDA margins are stable at 3.72% and 10.68% respectively, though room for improvement remains.

Balance Sheet

The Debt-to-Equity ratio is reasonable at 0.27, indicating a balanced leverage. Return on Equity is moderate at 4.85%, suggesting efficient asset utilization. The company maintains a good Equity Ratio of 62.06%, supporting financial stability. Overall, the balance sheet reflects sound financial health with manageable debt levels.

Cash Flow

Operating Cash Flow has increased significantly to €31.34M, showcasing strong cash-generating ability. Free Cash Flow to Net Income ratio is 1.02, indicating effective cash management. Free Cash Flow grew by 66.37%, reflecting improved financial flexibility. The company is well-positioned to meet its short-term obligations and invest in growth opportunities.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
331.83M	338.89M	316.09M	271.15M	236.23M	230.08M
	Gross Profit
114.77M	195.68M	175.03M	69.58M	144.98M	140.40M
	EBIT
14.04M	12.61M	10.51M	9.37M	8.86M	9.23M
	EBITDA
38.60M	36.18M	33.89M	30.44M	24.66M	24.31M
	Net Income Common Stockholders
9.55M	10.38M	9.41M	8.11M	5.09M	5.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.60M	16.08M	6.36M	6.45M	5.16M	11.69M
	Total Assets
346.86M	344.85M	330.55M	321.19M	324.98M	317.15M
	Total Debt
65.36M	58.52M	53.49M	61.24M	67.38M	57.02M
	Net Debt
56.06M	48.03M	47.96M	54.79M	62.32M	45.43M
	Total Liabilities
134.80M	130.90M	126.29M	122.94M	136.46M	132.67M
	Stockholders Equity
212.17M	213.97M	204.35M	194.63M	188.59M	184.55M
Cash Flow		Free Cash Flow
0.00	10.56M	6.34M	4.75M	-5.26M	6.55M
	Operating Cash Flow
0.00	31.34M	19.11M	16.15M	14.50M	22.50M
	Investing Cash Flow
0.00	-31.96M	-12.88M	-12.72M	-34.70M	-30.70M
	Financing Cash Flow
0.00	5.59M	-7.16M	-2.04M	13.67M	9.62M

LABORATORIO REIG JOFRE Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:RJF, the sentiment is Neutral. The current price of 3.12 is below the 20-day moving average (MA) of 3.19, above the 50-day MA of 2.97, and above the 200-day MA of 2.76, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 49.80 is Neutral, neither overbought nor oversold. The STOCH value of 17.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:RJF.

LABORATORIO REIG JOFRE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAE	80 Outperform	€1.41B	12.66	16.04%	1.81%	9.42%	20.43%
ROVI	78 Outperform	€2.83B	20.54	25.24%	1.59%	-1.49%	4.04%
RJF	75 Outperform	€250.68M	23.08	5.11%	1.28%	5.10%	20.61%
ALM	64 Neutral	€2.35B	228.33	0.69%	1.68%	10.20%	―
ORY	55 Neutral	€216.26M	―	-5.48%	―	―	-36.82%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
ATRY	44 Neutral	€208.18M	―	-11.64%	―	5.54%	30.33%

LABORATORIO REIG JOFRE Corporate Events

Reig Jofre Announces Free Capital Increase and Flexible Dividend Options

Reig Jofre announced the execution of a free capital increase, allowing shareholders to receive preferential subscription rights. Shareholders can choose to exchange these rights for new shares, sell them for cash to the company or on the market, or combine these options, with the trading period for these rights set from May 15 to 29, 2025.

Reig Jofre Announces Board Secretary Change

LABORATORIO REIG JOFRE, S.A. announced the resignation of Mr. Adolf Rousaud Viñas as Non-Director Secretary of the Board of Directors, effective April 30, 2025, due to personal reasons. The company expressed gratitude for his contributions to the board’s evolution and professionalization. Mr. Iñaki Frías Inchausti, a practicing lawyer, has been appointed as the new Non-Director Secretary, following a favorable report from the Appointments, Remuneration, and Sustainability Committee.

Reig Jofre Announces Flexible Dividend Options Through Capital Increase

Reig Jofre has announced the execution of a capital increase through a ‘scrip dividend’ or flexible dividend, allowing shareholders to receive either free shares or cash equivalent to a dividend payment. This move, approved by the Board of Directors, aims to provide shareholders with multiple options for their dividends, potentially impacting the company’s capital structure and shareholder value.

REIG JOFRE’s Q1 2025 Results: Operational Gains and International Expansion

REIG JOFRE reported a 12% increase in net results for the first quarter of 2025, driven by operational improvements and international growth, with revenues reaching 88 million euros. The company’s strategic focus on international markets, particularly in Europe and Asia, has led to a significant increase in sales outside Spain, now accounting for 60% of total revenues, while domestic sales decreased by 10%.

REIG JOFRE Secures 13 Million Euro Grant for Pharmaceutical Innovation

REIG JOFRE has been awarded a 13 million euro grant from the CDTi as part of the European IPCEI Med4Cure project, aimed at boosting pharmaceutical innovation. This grant supports REIG JOFRE’s EMINTECH project, which focuses on tackling global health challenges such as antimicrobial resistance and rare diseases through advanced therapies and cutting-edge technologies, enhancing the company’s strategic alignment with European health objectives.